Popular on Amzeal
- America's Hometown Thanksgiving Parade in Plymouth, MA, on Saturday, November 21, 2026 - 215
- Immerse Yourself in the Historic Tochigi Autumn Festival, Celebrated Every Two Years Since 1874 - 213
- XImagineAI Upgrades Its Multi-Model AI Video Generator for Image to Video and Text to Video - 176
- Unlocking the Next Phase of Growth with New AI Innovations; Targeting 2027 as Breakeven; Revenue Momentum Accelerates: ZenaTech (N A S D A Q: ZENA) - 136
- ZenaTech (NAS DAQ: ZENA) $1 Million in New Utility Contracts- Potential $2.5 Million Follow-On Opportunity Puts Its Drone Business in the Spotlight! - 134
- Paraguay Expedition Offers a Different View of Human Resilience - 131
- Patio Door Repair Long Island: Port Washington Homeowners Can Restore Sticking Sliding Doors - 122
- Hospital Direct Medical Equipment Company Seeing Growth in Used Refurbished Medical Equipment Sales - 122
- Mr Hospital Bed Cites Hill Rom Hospital Bed Models Best Value Home Care Hospital Beds 2026 - 120
- Award-Winning American Hotelier Opens Art-Filled Luxury Cottage in Norfolk, England - 120
Similar on Amzeal
- Boston Industrial Solutions Introduces the New Volta® M100 Pad Printing Machine
- Record Q3 Revenue and Gross Profit Delivered: Revenue Surges 40%, Gross Margin Soars to 36% & Adjusted EBITDA Loss Narrows 64% for Cycurion, Inc $CYCU
- UK Financial Ltd Launches MayaSwap On MAYA CHAIN To Facilitate UKFLMS-For-Gold Swaps, Officially Transforming UKFLMS From Meme Into A Real-World Asset
- Massive Acquisition Into Defense With STS for Virtuix Holdings; $40 Million Revenue Business Will Accelerate Growth Transforming Market Position
- Commercial Sales for U.S.-Made, Preservative-Free Ketamine Amid Long-Runnin Shortage Following FDA Approval by NRx Pharmaceuticals, Inc
- Kitchen Table Economics: An Invitation to Think Differently
- TCA VG: 2025 Funding Climbs to $9M across 43 Companies; Cumulative Returns Reach 5.3 MOIC & 22% IRR
- Commercial Sales Launch Following FDA Approval; National Sales Force Now in Action as January Shipments and Major Market Opportunity Take Shape
- New Six-Figure Media Agreement Builds Powerful Momentum, Expanding Government Contracts, FBI Access and Growing AI Recognition: Cyabra (NAS DAQ: CYAB)
- The 4th Annual Newark Summit for Economic Development, Placemaking & Innovation Returns on December 8th
Braeden Lichti - What's the Outlook for Biopharma in 2020?
Amzeal News/10367876
VANCOUVER, British Columbia - Amzeal -- COVID-19 put a damper on the international economy in the first three months of 2020. In fact, the first quarter of 2020 represented the worst quarter ever for the Dow Jones Industrial Average or DJIA, with a year-to-date loss of 23% and impacts seen in all 11 sectors of the economy.
However, analysts now believe the economy is making a v-shaped recovery, as the current year-to-date change of the DJIA stands at a loss of just 3.9%. Over the past few months, the DJIA has recouped its year-to-date loss by about 20%, and international economies reopen, analysts believe that things will only improve.
Biopharma has Thrived in the Time of COVID-19
Biopharma is one of the industries which has the most to gain from the COVID-19 pandemic, as activity in the sector has ramped up in recent months to yield curative therapies and vaccines for the novel coronavirus. The health sector, which includes biotech and pharmaceutical companies, has outperformed the S&P 500 in recent months despite the pandemic, making it one of the few areas of the economy that has actually thrived in the current environment.
More on Amzeal News
Biopharma Deals of 2020
While 2018 and 2019 were exciting years for Biopharma mergers and acquisitions (M&A), 2020 has been relatively uneventful for biopharma deals. In 2019, worldwide biopharma M&A in terms of completed and announced deals reached a record $254 billion, an increase of about $100 from 2018. Notable deals in 2019 included BMS/Celgene (valued at $74 billion, and the third largest acquisition in pharma history) and Abbvie/Allergan (with a valuation of $63 billion). This year, the worldwide economic slowdown and COVID-19-related downturn interfered with the normal day-to-day operations of all businesses. It is likely that, as the economy picks up again and the DJIA hits a new record, with ramifications for biopharma businesses which seek to expand and acquire smaller companies, but it remains too early to tell.
Biopharma Outlook for Q3 and Q4 of 2020 May Be Tied to Operation Warp Speed and COVID-19
Clearly, the COVID-19 crisis has presented new opportunities for biopharma companies which conduct work relevant to treatments and vaccines for the novel coronavirus. It is therefore likely that economic growth in biopharma in the remaining quarters of 2020 will be tied to progress towards a vaccine or cure to combat the global pandemic. In the United States, President Donald Trump has announced federal partnerships with several biotech companies in what is being called Operation Warp Speed (OWS) to facilitate and expedite the development of a vaccine to help Americans and people around the world get back to their normal day-to-day lives and avoid further deaths and economic destruction as a result of COVID-19.
More on Amzeal News
Appointed to lead OWS is Dr. Moncef Slaoui, a venture capitalist and former Chairman of Global Research and Development and Chairman of Global Vaccines at GlaxoSmithKline. The five finalists in this effort are AstraZeneca (US: AZN), Pfizer (US: PFE), Merck (US: MRK), Johnson & Johnson (US: JNJ), and Moderna (US: MRNA).
These companies will likely see economic growth due to their leadership on the COVID-19 vaccine effort, and are likely to outpace other companies in biopharma as the world works toward developing a safe an effective vaccine to defeat COVID-19.
Conclusion
COVID-19 has dramatically changed the world that we live in, and it is likely that global efforts to develop a vaccine may be responsible for the growth of biopharma in the last two quarters of 2020. While nobody can predict the future, it appears likely that economic growth will remain tied to those areas of the economy that interface directly with and are tied to the COVID-19 pandemic.
However, analysts now believe the economy is making a v-shaped recovery, as the current year-to-date change of the DJIA stands at a loss of just 3.9%. Over the past few months, the DJIA has recouped its year-to-date loss by about 20%, and international economies reopen, analysts believe that things will only improve.
Biopharma has Thrived in the Time of COVID-19
Biopharma is one of the industries which has the most to gain from the COVID-19 pandemic, as activity in the sector has ramped up in recent months to yield curative therapies and vaccines for the novel coronavirus. The health sector, which includes biotech and pharmaceutical companies, has outperformed the S&P 500 in recent months despite the pandemic, making it one of the few areas of the economy that has actually thrived in the current environment.
More on Amzeal News
- Proper Launches ProperMDM, Completing Its End-to-End Android Solution
- A Diwali Celebration with Heritage at South Brunswick Residents & American Properties
- Law Offices of Larry E. Bray, P.A. Wins Fourth District Appeal Clarifying Limits of Florida's Offer of Judgment Statute
- L-Tron's Mobile Driver's License Reader (mDLR-1) Featured in WHEC/News10NBC Story
- Parental control app for iPhone SimpleSentinel launches on Product Hunt: limits a child can't undo
Biopharma Deals of 2020
While 2018 and 2019 were exciting years for Biopharma mergers and acquisitions (M&A), 2020 has been relatively uneventful for biopharma deals. In 2019, worldwide biopharma M&A in terms of completed and announced deals reached a record $254 billion, an increase of about $100 from 2018. Notable deals in 2019 included BMS/Celgene (valued at $74 billion, and the third largest acquisition in pharma history) and Abbvie/Allergan (with a valuation of $63 billion). This year, the worldwide economic slowdown and COVID-19-related downturn interfered with the normal day-to-day operations of all businesses. It is likely that, as the economy picks up again and the DJIA hits a new record, with ramifications for biopharma businesses which seek to expand and acquire smaller companies, but it remains too early to tell.
Biopharma Outlook for Q3 and Q4 of 2020 May Be Tied to Operation Warp Speed and COVID-19
Clearly, the COVID-19 crisis has presented new opportunities for biopharma companies which conduct work relevant to treatments and vaccines for the novel coronavirus. It is therefore likely that economic growth in biopharma in the remaining quarters of 2020 will be tied to progress towards a vaccine or cure to combat the global pandemic. In the United States, President Donald Trump has announced federal partnerships with several biotech companies in what is being called Operation Warp Speed (OWS) to facilitate and expedite the development of a vaccine to help Americans and people around the world get back to their normal day-to-day lives and avoid further deaths and economic destruction as a result of COVID-19.
More on Amzeal News
- Holiday Magic Returns to Downtown Downers Grove November 27-29
- What If the Greatest Gift This Holiday Season Came in a Dream of Your Loved One in Spirit?
- Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Minneapolis
- Techsmarter's Turnaround Gains Momentum as Company Shifts Toward Outdoor Technology
- LGF Lab Gas Flow Launches Fully Automatic Laboratory Gas Changeover Manifold System with Ultra High Purity Gas Regulator Valve
Appointed to lead OWS is Dr. Moncef Slaoui, a venture capitalist and former Chairman of Global Research and Development and Chairman of Global Vaccines at GlaxoSmithKline. The five finalists in this effort are AstraZeneca (US: AZN), Pfizer (US: PFE), Merck (US: MRK), Johnson & Johnson (US: JNJ), and Moderna (US: MRNA).
These companies will likely see economic growth due to their leadership on the COVID-19 vaccine effort, and are likely to outpace other companies in biopharma as the world works toward developing a safe an effective vaccine to defeat COVID-19.
Conclusion
COVID-19 has dramatically changed the world that we live in, and it is likely that global efforts to develop a vaccine may be responsible for the growth of biopharma in the last two quarters of 2020. While nobody can predict the future, it appears likely that economic growth will remain tied to those areas of the economy that interface directly with and are tied to the COVID-19 pandemic.
Source: Braeden William Lichti
0 Comments
Latest on Amzeal News
- Turkish Engineer Who Cracked Wall Street's Algorithm Launches Hermes AI Analyzer
- UK Financial Ltd Launches MayaSwap On MAYA CHAIN To Facilitate UKFLMS-For-Gold Swaps, Officially Transforming UKFLMS From Meme Into A Real-World Asset
- South Beach Global Launches "One Cosmos, Curious Minds" — How Science Learned to Correct Itself
- DOR Issues Statement: NOV 13 FAA Ground Stop, Calls for the Logs Behind the Official Explanation
- Entrepreneur Nouho M Kanneh Talks Family, Faith and a $37 Million Portfolio in New Interview
- Emerald Williams Selected to Super Lawyers Rising Stars 2022-2026
- Geopolitics and Consolidation Reshape the Timing Components Landscape
- Kerbway launches with £500,000 to bring fleet sharing to UK organisations
- Electric Work Vans Can Run Multiple Tools at Once – Inside and Out
- Massive Acquisition Into Defense With STS for Virtuix Holdings; $40 Million Revenue Business Will Accelerate Growth Transforming Market Position
- Orlando Real Estate Broker Bent Danholm Wins 2026 Goody Business Book Award for The Architecture of Demand
- Commercial Sales for U.S.-Made, Preservative-Free Ketamine Amid Long-Runnin Shortage Following FDA Approval by NRx Pharmaceuticals, Inc
- UpgradeX Highlights Home Electrification Solutions for Australian Households This Black Friday
- The King Returns: Satirical December 2026 Rematch Sees Challenger Delayed by a Christmas Light Installation
- Central Florida Businesses Lose Customers to Unanswered Phones — Crown Glover Technologies' Assistant Answers Them on the Number They Already Have
- LCH2 Awarded Additional $1 Million to Advance Lewis County Clean Energy Campus
- Security Planning Tips For Your Holiday Event From Access Patrol Services
- Contracting Resources Group Receives 2026 HIRE Vets Platinum Medallion Award
- Business News & Info Goes Inside Paragon FX Group's Hunt for Original Film Props
- Looop helps families know their Loved Ones are safe, no matter the distance, starting with their health
